AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2088770 — intervention group
Group type: EXPERIMENTAL
Intervention: IdB 1016 (360 mg silybin equivalent)
Number of subjects: 9
Study 2088770 — intervention group
Group type: COMPARATOR
Intervention: Silymarin (360 mg silybin equivalent)
Number of subjects: 9
Study 2088770 — intervention group
Group type: EXPERIMENTAL
Intervention: IdB 1016 (120 mg b.i.d. for 8 days)
Number of subjects: 9
Study 2088770 — intervention group
Group type: EXPERIMENTAL
Intervention: IdB 1016
Number of subjects: 9
Study 276348 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG alone
Number of subjects: 134
Study 276348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour cell vaccine
Number of subjects: 134
Study 276348 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study 31976567 — intervention group
Group type: EXPERIMENTAL
Intervention: OSFE with deproteinized bovine bone mineral (Group 1)
Number of subjects: 45
Study 31976567 — intervention group
Group type: COMPARATOR
Intervention: OSFE without grafting (Group 2)
Number of subjects: 45
Study 31976567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 28541810 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-, glutamine-, and antioxidant-enriched oral nutrition supplement (S)
Number of subjects: 18
Study 28541810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 18
Study 28541810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (S and P)
Number of subjects: 18
Study 27295381 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelfoam patching
Number of subjects: 185
Study 27295381 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bFGF application
Number of subjects: 185
Study 27295381 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% Ofloxacin eardrops (OFLX)
Number of subjects: 185
Study 27295381 — intervention group
Group type: COMPARATOR
Intervention: Conservative observation
Number of subjects: 185
Study 24754265 — intervention group
Group type: EXPERIMENTAL
Intervention: Skull vibration-induced nystagmus test (SVINT) with vibratory stimulations at 60 Hz and 100 Hz applied on the vertex and mastoid.
Number of subjects: 55
Study 24754265 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 subjects)
Number of subjects: 55
Study 23537456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy follow-up (PF) via clinical pharmacy intervention at monthly visits over a 3-month follow-up period
Number of subjects: 68
Study 23537456 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (Control Group)
Number of subjects: 68
Study 20613498 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine stenting with drug-eluting stents (DES) in both branches (group MV plus SB)
Number of subjects: 108
Study 20613498 — intervention group
Group type: COMPARATOR
Intervention: Provisional stenting with DES placement in the main branch only (group MV)
Number of subjects: 108
Study 19010201 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 10 ppm from the start of LT until 48 hours afterward
Number of subjects: 32
Study 19010201 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iNO treatment)
Number of subjects: 32
Study 19010201 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 32
Study 16638037 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 16638037 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 0
Study 16638037 — intervention group
Group type: COMPARATOR
Intervention: Standard first-line fertility management
Number of subjects: 0
Study 16638037 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and clomiphene citrate
Number of subjects: 0
Study 14672246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritionally-sourced TRP (1.8 g daily)
Number of subjects: 50
Study 14672246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11013378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole (50-200 mg per day)
Number of subjects: 3734
Study 9283509 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d)
Number of subjects: 97
Study 9283509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 8345068 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle-stimulating hormone (FSH) (Metrodin)
Number of subjects: 24
Study 8345068 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotrophin (HMG) (Pergonal)
Number of subjects: 24
Study 8345068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse interval of 30 min
Number of subjects: 24
Study 8345068 — intervention group
Group type: COMPARATOR
Intervention: Pulse interval of 120 min
Number of subjects: 24
Study 8345068 — intervention group
Group type: COMPARATOR
Intervention: Addition of LH in HMG
Number of subjects: 24
Study 2942163 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60
Study 2942163 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 60
Study 2942163 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 30248152 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Tb
Number of subjects: 1090
Study 30248152 — intervention group
Group type: COMPARATOR
Intervention: TST
Number of subjects: 1090
Study 30248152 — intervention group
Group type: COMPARATOR
Intervention: QFT
Number of subjects: 1090
Study 30248152 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Tb and TST
Number of subjects: 1090
Study 27535024 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually-tailored telephone tobacco intervention combining counseling for tobacco use and related issues including depressive symptoms, risky alcohol use, and weight concerns
Number of subjects: 63
Study 27535024 — intervention group
Group type: COMPARATOR
Intervention: Quitline Referral
Number of subjects: 63
Study 25035121 — intervention group
Group type: EXPERIMENTAL
Intervention: 3mg THC
Number of subjects: 12
Study 25035121 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg THC
Number of subjects: 12
Study 25035121 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5mg THC
Number of subjects: 12
Study 25035121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22586006 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care management program (CCMP)
Number of subjects: 426
Study 22586006 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 426
Study 20462632 — intervention group
Group type: EXPERIMENTAL
Intervention: Active art therapy
Number of subjects: 22
Study 20462632 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 22
Study 18337480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CVVHDF (35 ml/kg per h)
Number of subjects: 200
Study 18337480 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CVVHDF (20 ml/kg per h)
Number of subjects: 200
Study 15968293 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD25 monoclonal antibody (basiliximab)
Number of subjects: 53
Study 15968293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no basiliximab)
Number of subjects: 53
Study 15968293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 11211367 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 198
Study 11211367 — intervention group
Group type: COMPARATOR
Intervention: Combined pharmacotherapy and behavioral treatment
Number of subjects: 198
Study 11211367 — intervention group
Group type: COMPARATOR
Intervention: Titration-determined dose
Number of subjects: 198
Study 11211367 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological changes
Number of subjects: 198
Study 9723557 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous pump spray (Rhinocort Aqua) 32, 64, 128, or 256 microg once daily for 6 weeks
Number of subjects: 478
Study 9723557 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous pump spray (256 microg)
Number of subjects: 478
Study 9723557 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous pump spray (any active treatment group)
Number of subjects: 478
Study 9723557 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous pump spray
Number of subjects: 478
Study 9723557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 7982869 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg per dose
Number of subjects: 47
Study 7982869 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.6 mg/kg per dose
Number of subjects: 47
Study 7982869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 2567584 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 120 micrograms/kg
Number of subjects: 10
Study 2567584 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 225 micrograms/kg
Number of subjects: 10
Study 2567584 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 23 micrograms/kg
Number of subjects: 10
Study 2567584 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 40 micrograms/kg
Number of subjects: 10
Study 2567584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 30 micrograms/kg
Number of subjects: 10
Study 2567584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 60 micrograms/kg
Number of subjects: 10
Study 2567584 — intervention group
Group type: EXPERIMENTAL
Intervention: d-tubocurarine 185 micrograms/kg
Number of subjects: 10
Study 2567584 — intervention group
Group type: EXPERIMENTAL
Intervention: d-tubocurarine 450 micrograms/kg
Number of subjects: 10
Study 5784612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic oestriol sulphate
Number of subjects: 0
Study 5784612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 223601 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium clofibrate and calcium carbonate (4C, 2 + 2 g/day for 6 months)
Number of subjects: 30
Study 223601 — intervention group
Group type: COMPARATOR
Intervention: clofibrate (1C, 2 g/day for 6 months)
Number of subjects: 30
Study 223601 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium clofibrate and calcium carbonate (4C)
Number of subjects: 30
Study 223601 — intervention group
Group type: COMPARATOR
Intervention: clofibrate (1C)
Number of subjects: 30
Study 31999518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tell me everything he [or she] eats throughout a day
Number of subjects: 99
Study 31999518 — intervention group
Group type: EXPERIMENTAL
Intervention: What kind of food does she [or he] eat?
Number of subjects: 99
Study 31999518 — intervention group
Group type: EXPERIMENTAL
Intervention: What kind of foods does he [or she] eat?
Number of subjects: 99
Study 31999518 — intervention group
Group type: COMPARATOR
Intervention: Diet history survey
Number of subjects: 99
Study 30630567 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Kyphoplasty (PKP)
Number of subjects: 100
Study 30630567 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Vertebroplasty (PVP)
Number of subjects: 100
Study 27836508 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (L. rhamnosus) HN001 probiotic treatment for 4 weeks
Number of subjects: 114
Study 27836508 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 114
Study 26163236 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mitomycin C (MMC)
Number of subjects: 30
Study 26163236 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 30
Study 23577900 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 7
Study 23577900 — intervention group
Group type: COMPARATOR
Intervention: Oral naltrexone
Number of subjects: 7
Study 21890526 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (40 minutes, three times a week for 3 months)
Number of subjects: 91
Study 21890526 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (recorded programme for 3 months)
Number of subjects: 91
Study 21890526 — intervention group
Group type: COMPARATOR
Intervention: Topiramate (daily use, titrated to maximum 200 mg/day for 3 months)
Number of subjects: 91
Study 18974973 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (posterior-inferior capsular plications)
Number of subjects: 40
Study 18974973 — intervention group
Group type: COMPARATOR
Intervention: Group A (no posterior-inferior capsular plications)
Number of subjects: 40
Study 17453387 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track program after total hip replacement
Number of subjects: 79
Study 17453387 — intervention group
Group type: COMPARATOR
Intervention: Non-consenters (control group)
Number of subjects: 79
Study 15047537 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate alone
Number of subjects: 176
Study 15047537 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate with primaquine
Number of subjects: 176
Study 15047537 — intervention group
Group type: COMPARATOR
Intervention: Quinine alone
Number of subjects: 176
Study 15047537 — intervention group
Group type: COMPARATOR
Intervention: Quinine with primaquine at 15 mg/day
Number of subjects: 176
Study 15047537 — intervention group
Group type: COMPARATOR
Intervention: Quinine with primaquine at 30 mg/day
Number of subjects: 176
Study 15047537 — intervention group
Group type: COMPARATOR
Intervention: Quinine with tetracycline
Number of subjects: 176
Study 11334202 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleting filters (group F)
Number of subjects: 40
Study 11334202 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 40
Study 9564064 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% intraperitoneal subdiaphragmatic lidocaine 40 ml and 0.5% bupivacaine 5 ml infiltration of cannula insertion sites
Number of subjects: 40
Study 9564064 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 40
Study 7994223 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and counselling programme with telephone follow-up (experimental group)
Number of subjects: 60
Study 7994223 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and counselling programme with telephone follow-up (experimental group) with partner participation
Number of subjects: 60
Study 7994223 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care only (control group)
Number of subjects: 60
Study 2535450 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-elemental diets
Number of subjects: 32
Study 2535450 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 32
Study 31846575 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine extended release for 12 weeks
Number of subjects: 500
Study 27871827 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 165
Study 27871827 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic infection with Mycoplasma hominis
Number of subjects: 165
Study 25594788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 30
Study 25594788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23669885 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe-TT₂R₂ score = 0-1
Number of subjects: 0
Study 23669885 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe-TT₂R₂ score ≥ 2
Number of subjects: 0
Study 23669885 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression model with nine independent predictors of TTR
Number of subjects: 0
Study 23669885 — intervention group
Group type: EXPERIMENTAL
Intervention: c-index of SAMe-TT₂R₂ score
Number of subjects: 0
Study 21372034 — intervention group
Group type: EXPERIMENTAL
Intervention: SR13668 (38 mg oral dose)
Number of subjects: 20
Study 19727884 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal oil capsules (340 mg EPA, 230 mg DPA, 450 mg DHA)
Number of subjects: 48
Study 19727884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules (210 mg EPA, 30 mg DPA, 810 mg DHA)
Number of subjects: 48
Study 19727884 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (containing sunola oil)
Number of subjects: 48
Study 17387133 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg of reconstituted HDL (CSL‐111)
Number of subjects: 183
Study 17387133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 183
Study 15114551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV) with volume guarantee (VG) (Vt = 5 ml/kg) (n = 30)
Number of subjects: 53
Study 15114551 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV) without volume guarantee (n = 23)
Number of subjects: 53
Study 11605121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide inhalation with RC-Cornet(R)
Number of subjects: 35
Study 11605121 — intervention group
Group type: COMPARATOR
Intervention: Ipratropiumbromide inhalation with conventional inhalation (Pari-system)
Number of subjects: 35
Study 7992674 — intervention group
Group type: EXPERIMENTAL
Intervention: Real smoking
Number of subjects: 15
Study 7992674 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 15
Study 2688737 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine 50 mg t.d.s.
Number of subjects: 18
Study 2688737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1079213 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg daily
Number of subjects: 12
Study 1079213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31741073 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of dexamethasone injected within 10 minutes of detected LOS in Group 2 (G2)
Number of subjects: 702
Study 31741073 — intervention group
Group type: COMPARATOR
Intervention: No intervention in Group 1 (G1)
Number of subjects: 702
Study 31870456 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (low frequency)
Number of subjects: 125
Study 31870456 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (high frequency)
Number of subjects: 125
Study 31870456 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (alternating frequency)
Number of subjects: 125
Study 31870456 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 125
Study 31870456 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 28327695 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive abutment group (immediate loading)
Number of subjects: 80
Study 28327695 — intervention group
Group type: COMPARATOR
Intervention: Repeated abutment changes group (delayed loading)
Number of subjects: 80
Study 25114060 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived stromal vascular fraction (SVF) injection
Number of subjects: 12
Study 23569370 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 500 μg
Number of subjects: 0
Study 23569370 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 500 μg/VI 25 μg
Number of subjects: 0
Study 23569370 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 240 mg (administered on days 9-13)
Number of subjects: 0
Study 20331687 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-specific transfusion (DST)
Number of subjects: 163
Study 20331687 — intervention group
Group type: EXPERIMENTAL
Intervention: Random transfusion
Number of subjects: 163
Study 20331687 — intervention group
Group type: COMPARATOR
Intervention: No transfusion (Control)
Number of subjects: 163
Study 20331687 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 163
Study 20331687 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed graft function patients
Number of subjects: 163
Study 19922877 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol in sorbate 0.5%
Number of subjects: 30
Study 19922877 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol gel-forming solution 0.5%
Number of subjects: 30
Study 19922877 — intervention group
Group type: COMPARATOR
Intervention: Timolol hemihydrate 0.5%
Number of subjects: 30
Study 17124643 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract WS 5570 (900 mg/d or 1800 mg/d)
Number of subjects: 133
Study 17124643 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20 mg/d or 40 mg/d)
Number of subjects: 133
Study 14704914 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Product (HP-guar gellable lubricant eye drop)
Number of subjects: 87
Study 14704914 — intervention group
Group type: COMPARATOR
Intervention: Control Product (carboxymethylcellulose)
Number of subjects: 87
Study 11336121 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dental office-based intervention for smokeless tobacco users
Number of subjects: 0
Study 11336121 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dental office-based intervention for smokers
Number of subjects: 0
Study 11336121 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshops for disseminating the smokeless tobacco intervention to DHCWs
Number of subjects: 0
Study 11336121 — intervention group
Group type: COMPARATOR
Intervention: Self-study for disseminating the smokeless tobacco intervention to DHCWs
Number of subjects: 0
Study 9643220 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin (0.25 mg daily of 0.1% tretinoin cream)
Number of subjects: 11
Study 9643220 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control
Number of subjects: 11
Study 8360602 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic apex locator
Number of subjects: 26
Study 8360602 — intervention group
Group type: COMPARATOR
Intervention: Radiographic method
Number of subjects: 26
Study 2426902 — intervention group
Group type: EXPERIMENTAL
Intervention: Various established topical and systemic treatment regimes
Number of subjects: 20
Study 31949084 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion (6 pmol/kg/min)
Number of subjects: 22
Study 31949084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 22
Study 31949084 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion
Number of subjects: 22